Caterpillar Inc. (NYSE:CAT) reported upbeat earnings for the fourth quarter on Thursday.For the fourth quarter of 2025, sales and revenues were $19.133 billion, up 18% from $16.215 billion in the prior-year period. Adjusted profit per share was $5.16, beating a $4.66 estimate, while revenue exceeded a $17.851 billion estimate.Fourth-quarter profit per diluted share (GAAP) was $5.12, compared with $5.78 a year earlier. Operating profit was $2.660 billion, down 9%, and operating profit margin was 13.9% versus ...

Core Insights - Hologic, Inc. reported adjusted EPS of $1.04 for Q1 fiscal 2026, a 1% increase year over year, but missed the Zacks Consensus Estimate by 4.46% [1] - The company's GAAP EPS was 79 cents, reflecting a 9.2% decrease year over year [1] Revenue Performance - Total revenues for the quarter reached $1.05 billion, up 2.5% year over year, but fell short of the Zacks Consensus Estimate by 2.14% [2] - U.S. revenues increased by 2% to $773.5 million, while international revenues rose 4% year over year to $274.3 million, although they decreased by 1% at constant exchange rates [2] Segment Analysis - Diagnostics revenues decreased by 1.3% year over year to $464.4 million, with Molecular Diagnostics revenues down 3.5% due to lower sales of COVID-19 tests [3] - Breast Health revenues increased by 1.8% to $375.9 million, driven by strong sales of Endomagnetics products [4] - GYN Surgical revenues surged 87% year over year to $180.8 million, primarily due to higher sales from the acquired Gynesonics business [4] - Skeletal Health revenues increased by 69% to $26.7 million, attributed to higher sales volume of Horizon DXA systems [4] Margin Performance - Adjusted gross margin decreased by 150 basis points to 60.1%, mainly due to increased tariff expenses [5] - Adjusted operating margin was reported at 29%, down 40 basis points [5] Financial Position - Hologic ended Q1 fiscal 2026 with cash and cash equivalents of $2.17 billion, an increase from $1.96 billion at the end of fiscal 2025 [6] - Total long-term debt remained stable at $2.51 billion [6] Operating Cash Flow - Net cash provided by operating activities was $229.9 million, compared to $189.3 million a year ago [8] Overall Assessment - Hologic's revenues and earnings missed estimates, with both gross and operating margins contracting, although there was year-over-year improvement in both metrics [9] - Weakness in Molecular Diagnostics was offset by stronger sales in other segments, particularly GYN Surgical [9]

Core Insights - Danaher reported a revenue of $24.568 billion for 2025, representing a 3.0% increase from $23.875 billion in 2024, with core business growth of 2.0% and a 1.0% contribution from currency fluctuations [2] - The company generated a free cash flow of $5.293 billion in 2025, demonstrating strong cash generation capabilities [1][3] Financial Performance - In Q4 2025, revenue reached $6.838 billion, a 4.5% increase from $6.538 billion in Q4 2024, with core business growth contributing 2.5% and currency fluctuations contributing 2.5% [2] - Adjusted operating profit margin for Q4 was 28.3%, down 130 basis points from 29.6% in Q4 2024; the full-year adjusted operating profit margin was 28.2%, a slight decrease of 40 basis points from 28.6% in 2024 [3] - Adjusted diluted earnings per share for Q4 was $2.23, a 4.0% year-over-year increase, while the full-year adjusted diluted earnings per share was $7.80, up 4.5% [3] Business Segment Performance - The Biotechnology segment led growth with Q4 revenue of $2.033 billion, a 9.0% year-over-year increase, and full-year revenue of $7.293 billion, an 8.0% increase [4] - The Life Sciences segment reported Q4 revenue of $2.085 billion, a 2.5% increase, with full-year revenue remaining stable at $7.334 billion [5][6] - The Diagnostics segment achieved Q4 revenue of $2.720 billion, a 3.0% increase, with full-year revenue of $9.941 billion, reflecting a 1.5% growth [7] 2026 Guidance - For 2026, Danaher expects core sales to grow between 3.0% and 6.0%, with the Biotechnology segment projected to grow approximately 6.0% [8] - The company anticipates adjusted diluted earnings per share to be between $8.35 and $8.50, with an adjusted operating profit margin of around 28.5% [8] Market Outlook - Danaher's CEO highlighted signs of recovery in the end markets served, particularly in the pharmaceutical sector, with strong demand for monoclonal antibody production and improvements in capital expenditure [9]

2025年全年，Meta总营收为2009.66亿美元，较2024年的1645.01亿美元增长22%；净利润为604.58亿美 元，较2024年的623.60亿美元下降3%。 Meta第四季度营收和每股收益均超出预期，推动股价在盘后大涨9%。(作者/箫雨) 凤凰网科技讯北京时间1月29日，脸书母公司Meta(NASDAQ:META)今天发布了截至12月31日的2025年 第四季度及全年财报。财报显示，Meta第四季度总营收为598.93亿美元，较上年同期的483.85亿美元增 长24%；净利润为227.68亿美元，较上年同期的208.38亿美元增长9%，其中现实实验室硬件部门营业亏 损60.2亿美元。 Meta CEO扎克伯格 ...

Core Insights - RTX Corporation reported strong fourth-quarter 2025 results with sales of $24.238 billion, a 12% increase from $21.623 billion in the previous year [1] - GAAP diluted EPS was $1.19, up from $1.10 year-over-year, including various adjustments [1] - Adjusted EPS rose 1% to $1.55, exceeding analyst estimates [2] Financial Performance - Fourth-quarter sales reached $24.238 billion, surpassing analyst expectations of $22.737 billion [2] - The company guided for adjusted sales of $92.0 billion to $93.0 billion for 2026, with organic sales growth projected at 5% to 6% [2] - Expected adjusted EPS for 2026 is between $6.60 and $6.80, compared to an estimate of $6.71 [2] - Free cash flow is anticipated to be between $8.25 billion and $8.75 billion [2] Market Reaction - Following the earnings announcement, RTX shares increased by 0.1% to $201.54 [3] - Analysts adjusted their price targets for RTX, with UBS raising it from $199 to $208 and RBC Capital from $220 to $230 [4]

Core Viewpoint - Sysco Corporation reported strong second-quarter fiscal 2026 earnings, exceeding analyst expectations for adjusted earnings per share and achieving a notable year-over-year sales increase [1][2]. Financial Performance - The company reported adjusted earnings per share of 99 cents, surpassing the analyst consensus estimate of 98 cents [1]. - Quarterly sales reached $20.762 billion, closely aligning with the expected $20.767 billion, reflecting a 3.0% year-over-year growth [1]. Growth Indicators - Sysco experienced its third consecutive quarter of improving local case growth, with USFS local case volume showing a positive growth of 1.2% in the quarter [2]. - The company anticipates fiscal 2026 adjusted EPS growth to be at the high end of its previously provided guidance range of $4.50-$4.60, consistent with long-term financial targets [2]. Adjusted EPS Outlook - Sysco's CFO indicated an increase in the full-year adjusted EPS outlook to the high end of the prior range, despite facing a $100 million headwind from lower incentive compensation in fiscal 2025, equating to $0.16 per diluted share [3]. Analyst Ratings and Price Targets - Barclays and Wells Fargo analysts maintained an Overweight rating on Sysco, raising their price targets from $88 to $92 [4]. - Piper Sandler maintained a Neutral rating while increasing the price target from $80 to $83 [4].

Core Insights - Booz Allen Hamilton Holding Corp. (BAH) reported mixed third-quarter fiscal 2026 results, with earnings exceeding the Zacks Consensus Estimate while revenues fell short [1] - The stock has declined 8.1% since the results were released on January 23, 2026, primarily due to the revenue miss and weak fiscal 2026 guidance [1] Revenue and Earnings - BAH expects revenues to be between $11.3 billion and $11.4 billion, down from the previous guidance of $11.3 billion to $11.5 billion, with the midpoint below the Zacks Consensus Estimate of $11.38 billion [2] - Revenue growth is projected at 5-6%, while free cash flow is anticipated to be in the range of $825 million to $900 million, revised from $850 million to $950 million [2] - Quarterly adjusted earnings per share (EPS) were reported at $1.77, beating the Zacks Consensus Estimate by 40.5% and increasing 14.2% year-over-year [3] - Total revenues for the quarter were $2.62 billion, missing the consensus estimate by 3.9% and decreasing 10.2% year-over-year [3] Backlog and Book-to-Bill Ratio - Total backlog increased by 1.5% year-over-year to $38 billion, but fell short of the estimate of $42.88 billion [4] - Funded backlog decreased by 9.7% to $4.21 billion, missing expectations, while unfunded backlog rose by 18.7% but was below the estimate [4] - Priced options declined by 2.2% to $24.19 billion, also missing expectations, with a book-to-bill ratio of 0.3 compared to 0.6 in the previous year [5] EBITDA and Margins - Adjusted EBITDA was $285 million, a decrease of 14.2% year-over-year, but exceeded the estimate of $282.6 million [6] - The adjusted EBITDA margin on revenues was 10.9%, down 50 basis points year-over-year [6] Balance Sheet and Cash Flow - BAH ended the quarter with cash and cash equivalents of $882 million, slightly down from $885 million in the previous quarter [7] - Long-term debt decreased by 1.5% to $3.86 billion compared to $3.92 billion at the end of fiscal 2025 [7] - The company generated $801 million in net cash from operating activities, with capital expenditure at $195 million and free cash flow reported at $248 million [7] Fiscal Year 2026 Outlook - BAH expects adjusted diluted EPS to be in the range of $5.95 to $6.15, an increase from the prior guidance of $5.45 to $5.65, with the midpoint above the Zacks Consensus Estimate of $5.69 [8] - Free cash flow is anticipated to remain in the range of $825 million to $900 million [8]

对于苹果2026财年第一季度财报，焦点将再次落在iPhone需求上，尤其是在中国。苹果在中国面临定价 压力和本土竞争对手的挑战。投资者希望看到近期促销活动和产品更新是否支撑了假日季的销量，以及 平均售价是否保持稳定。尽管苹果不再披露销量，但地区收入趋势将被密切关注，以作为潜在需求的参 考。iPhone仍是苹果最大的单一产品类别，并驱动其他产品和服务生态系统的参与度。 智通财经APP获悉，周一，苹果(AAPL.US)涨逾2%，报254.67美元。消息面上，苹果公司将于1月29日 (周四)美股盘后公布2026财年第一季度业绩。苹果预计将实现稳健的营收、净利润和每股收益增长。市 场目前预计，苹果Q1营收将同比增长11.3%至1384.2亿美元，净利润将同比增长8.4%至393.8亿美元，每 股收益将同比增长11.2%至2.67美元。 ...

Group 1 - The core point of the article is that GE has consistently outperformed Wall Street's earnings estimates for 12 consecutive quarters [1]

Core Viewpoint - D.R. Horton reported strong earnings for Q1 of fiscal 2026, exceeding analyst expectations despite a decline in revenue compared to the previous year [1][2]. Financial Performance - Net income for the quarter was $594.8 million, or $2.03 per diluted share, down from $844.9 million, or $2.61 per diluted share, in the same quarter last year [1]. - Revenue was $6.887 billion, a decrease from $7.613 billion a year earlier, but still surpassed the consensus estimate of $6.603 billion [2]. Shareholder Returns - The company returned $801.2 million to shareholders through share repurchases and dividends during the quarter, leveraging its strong financial position and cash flow generation [2]. Stock Performance - Following the earnings announcement, D.R. Horton shares increased by 3.1%, trading at $157.93 [2]. Analyst Ratings and Price Targets - Barclays analyst Matthew Bouley maintained an Equal-Weight rating and lowered the price target from $132 to $129 [4]. - B of A Securities analyst Rafe Jadrosich maintained a Neutral rating and cut the price target from $162 to $158 [4]. - Evercore ISI Group analyst Stephen Kim maintained an In-Line rating and raised the price target from $167 to $169 [4].